Evogene Schedules First Quarter 2024 Financial Results Release
Evogene Schedules First Quarter 2024 Financial Results Release
Zoom conference call scheduled for 9:00 AM ET
Zoom 电话会议定于美国东部时间上午 9:00
REHOVOT, Israel, May 9, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.
以色列雷霍沃特，2024 年 5 月 9 日 /PRNewswire/-- Evogene Ltd。纳斯达克股票代码：EVGN）（TASE: EVGN）是一家旨在彻底改变生命科学产品发现和开发的领先计算生物学公司，今天宣布将在上线发布2024年第一季度的财务业绩 2024年5月23日，星期四。
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
当天晚些时候，公司管理层将举办 美国东部时间上午 9:00 召开电话会议，讨论结果 （以色列时间下午 4:00）。
To join the conference, please register in advance:
要参加会议，请提前注册：
The entire conference will be available online on the company's website a few days after.
几天后，整个会议将在公司的网站上在线公布。
About Evogene:
关于 Evogene：
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene Ltd.（纳斯达克股票代码：EVGN，TASE：EVGN）是一家利用大数据和人工智能的计算生物学公司，旨在通过利用尖端技术来提高成功概率，同时减少开发时间和成本，从而彻底改变基于生命科学的产品的开发。
Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene 建立了三种独特的技术引擎- 微升压 AI， ChemPass AI 和 生成器人工智能。每个技术引擎都专注于发现和开发基于以下核心成分之一的产品：微生物（MicroBoost）、小分子（ChemPass AI）和遗传元素（生成器人工智能)。
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:
Evogene使用其技术引擎通过战略伙伴关系和合作开发产品，其四家子公司包括：
- Biomica Ltd. () - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
- Lavie Bio Ltd. () - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
- AgPlenus Ltd. () - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
- Casterra Ag Ltd. () - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.
- Biomica 有限公司 ()-开发和推进基于微生物组的新型疗法，用于治疗人类疾病 微增强人工智能;
- Lavie Bio 有限公司 () - 开发和商业推进基于微生物组的农业生物制剂，由 微增强人工智能;
- agPlenus 有限公司 ()-开发下一代农业化学品，以实现有效和可持续的作物保护 ChemPass AI;
- Casterra Ag 有限公司 ()-在工业规模上为生物燃料和其他行业开发和销售具有高产量和高品位含油量的优质蓖麻种子品种 生成器人工智能。
For more information, please visit: .
欲了解更多信息，请访问：。
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
[email protected]
Tel: +972-8-9311901
联系人
雷切尔·波美兰兹·格伯
Evogene 投资者关系主管
[电子邮件保护]
电话：+972-8-9311901
Logo:
徽标：
SOURCE Evogene
来源 Evogene
译文内容由第三方软件翻译。